OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT ID: NCT04757610

Last Updated: 2025-07-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

986 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-12

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302

0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals.

Group Type EXPERIMENTAL

2.0 mg OPT-302

Intervention Type BIOLOGICAL

intravitreal injection

0.5 mg ranibizumab

Intervention Type BIOLOGICAL

intravitreal injection

0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302

0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not.

Group Type EXPERIMENTAL

2.0 mg OPT-302

Intervention Type BIOLOGICAL

intravitreal injection

0.5 mg ranibizumab

Intervention Type BIOLOGICAL

intravitreal injection

0.5 mg ranibizumab with sham

0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals.

Sham intravitreal injection administered at 4-weekly intervals.

Group Type SHAM_COMPARATOR

0.5 mg ranibizumab

Intervention Type BIOLOGICAL

intravitreal injection

Sham

Intervention Type PROCEDURE

intravitreal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2.0 mg OPT-302

intravitreal injection

Intervention Type BIOLOGICAL

0.5 mg ranibizumab

intravitreal injection

Intervention Type BIOLOGICAL

Sham

intravitreal injection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
* An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.

Exclusion Criteria

* Any previous treatment for neovascular AMD.
* Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
* Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Opthea Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ShORe Investigational Site

Phoenix, Arizona, United States

Site Status

ShORe Investigational Site

Phoenix, Arizona, United States

Site Status

ShORe Investigational Site

Tucson, Arizona, United States

Site Status

ShORe Investigational Site

Bakersfield, California, United States

Site Status

ShORe Investigational Site

Campbell, California, United States

Site Status

ShORe Investigational Site

Encino, California, United States

Site Status

ShORe Investigational Site

Fullerton, California, United States

Site Status

ShORe Investigational Site

Glendale, California, United States

Site Status

ShORe Investigational Site

Huntington Beach, California, United States

Site Status

ShORe Investigational Site

Laguna Hills, California, United States

Site Status

ShORe Investigational Site

Long Beach, California, United States

Site Status

ShORe Investigational Site

Los Angeles, California, United States

Site Status

ShORe Investigational Site

Mountain View, California, United States

Site Status

ShORe Investigational Site

Palm Desert, California, United States

Site Status

ShORe Investigational site

Pasadena, California, United States

Site Status

ShORe Investiagtional Site

Poway, California, United States

Site Status

ShORe Investigational Site

Redlands, California, United States

Site Status

ShORe Investigational Site

Sacramento, California, United States

Site Status

ShORe Investigational Site

Santa Ana, California, United States

Site Status

ShORe Investigational Site

Torrance, California, United States

Site Status

ShORe Investigational Site

Colorado Springs, Colorado, United States

Site Status

ShORe Investigational Site

Denver, Colorado, United States

Site Status

ShORe Investigational Site

Lakewood, Colorado, United States

Site Status

ShORe Investigational Site

Longmont, Colorado, United States

Site Status

ShORe Investigational Site

Clearwater, Florida, United States

Site Status

ShORe Investigational Site

Fort Lauderdale, Florida, United States

Site Status

ShORe Investigational Site

Fort Myers, Florida, United States

Site Status

ShORe Investigational Site

Gainesville, Florida, United States

Site Status

ShORe Investigational Site

Lakeland, Florida, United States

Site Status

ShORe Investigational Site

Pensacola, Florida, United States

Site Status

ShORe Investigational Site

Pinellas Park, Florida, United States

Site Status

ShORe Investigational Site

Temple Terrace, Florida, United States

Site Status

ShORe Investigational Site

Augusta, Georgia, United States

Site Status

ShORe Investigational Site

Sandy Springs, Georgia, United States

Site Status

ShORe Investigational Site

Lemont, Illinois, United States

Site Status

ShORe Investigational Site

Indianapolis, Indiana, United States

Site Status

ShORe Investigational Site

Baltimore, Maryland, United States

Site Status

ShORe Investigational Site

Baltimore, Maryland, United States

Site Status

ShORe Investigational Site

Hagerstown, Maryland, United States

Site Status

ShORe Investigational Site

Towson, Maryland, United States

Site Status

ShORe Investigational Site

Springfield, Massachusetts, United States

Site Status

ShORe Investigational Site

Minneapolis, Minnesota, United States

Site Status

ShORe Investigational Site

St Louis, Missouri, United States

Site Status

ShORe Investigational Site

Reno, Nevada, United States

Site Status

ShORe Investigational Site

Bloomfield, New Jersey, United States

Site Status

ShORe Investigational Site

Toms River, New Jersey, United States

Site Status

ShORe Investigational Site

Hauppauge, New York, United States

Site Status

ShORe Investigational Site

Liverpool, New York, United States

Site Status

ShORe Investigational Site

Wake Forest, North Carolina, United States

Site Status

ShORe Investigational Site

Fargo, North Dakota, United States

Site Status

ShORe Investigational Site

Edmond, Oklahoma, United States

Site Status

ShORe Investigational Site

Tulsa, Oklahoma, United States

Site Status

ShORe Investigational Site

Eugene, Oregon, United States

Site Status

ShORe Investigational Site

Portland, Oregon, United States

Site Status

ShORe Investigational Site

Portland, Oregon, United States

Site Status

ShORe Investigational Site

Salem, Oregon, United States

Site Status

ShORe Investigational Site

Erie, Pennsylvania, United States

Site Status

ShORe Investigational Site

Beaufort, South Carolina, United States

Site Status

ShORe Investigational Site

Ladson, South Carolina, United States

Site Status

ShORe Investigational Site

Nashville, Tennessee, United States

Site Status

ShORe Investigational Site

Arlington, Texas, United States

Site Status

ShORe Investigational Site

Austin, Texas, United States

Site Status

ShORe Investigational Site

Austin, Texas, United States

Site Status

ShORe Investigational Site

Bellaire, Texas, United States

Site Status

ShORe Investigational Site

Dallas, Texas, United States

Site Status

ShORe Investigational Site

Houston, Texas, United States

Site Status

ShORe Investigational Site

Katy, Texas, United States

Site Status

ShORe Investigational Site

McAllen, Texas, United States

Site Status

ShORe Investigational Site

San Antonio, Texas, United States

Site Status

ShORe Investigational Site

San Antonio, Texas, United States

Site Status

ShORe Investigational Site

San Antonio, Texas, United States

Site Status

ShORe Investigational Site

Tyler, Texas, United States

Site Status

ShORe Investigational Site

Willow Park, Texas, United States

Site Status

ShORe Investigational Site

Salt Lake City, Utah, United States

Site Status

ShORe Investigational Site

Charlottesville, Virginia, United States

Site Status

ShORe Investigational Site

Lynchburg, Virginia, United States

Site Status

ShORe Investigational Site

Capital Federal, Ciudad Autonoma Buenos Aires, Argentina

Site Status

ShORe Investigational Site

Rosario, Santa Fe Province, Argentina

Site Status

ShORe Investigational Site

Rosario, Sante Fe, Argentina

Site Status

ShORe Investigational Site

Buenos Aires, , Argentina

Site Status

ShORe Investigational Site

Buenos Aires, , Argentina

Site Status

ShORe Investigational Site

Ciudad Autonoma de Buenos Aire, , Argentina

Site Status

ShORe Investigational Site

Córdoba, , Argentina

Site Status

ShORe Investigational Site

Hurstville, New South Wales, Australia

Site Status

ShORe Investigational Site

Melbourne, Victoria, Australia

Site Status

ShORe Investigational Site

Vitória, Cordoba, Brazil

Site Status

ShORe Investigational Site

Goiânia, Goiás, Brazil

Site Status

ShORe Investigational Site

Faxinal do Soturno, Rio Grande do Sul, Brazil

Site Status

ShORe Investigational site

Blumenau, Santa Catarina, Brazil

Site Status

ShORe Investigational Site

Santo André, São Paulo, Brazil

Site Status

ShORe Investigational Site

São Paulo, , Brazil

Site Status

ShORe Investigational Site

São Paulo, , Brazil

Site Status

ShORe Investigational Site

Sofia, , Bulgaria

Site Status

ShORe Investigational Site

Calgary, Alberta, Canada

Site Status

ShORe Investigational Site

Edmonton, Alberta, Canada

Site Status

ShORe Investigational Site

Edmonton, Alberta, Canada

Site Status

ShORe Investigational Site

Mississauga, Ontario, Canada

Site Status

ShORe Investigational Site

Medellín, , Colombia

Site Status

ShORe Investigational Site

Pardubice, , Czechia

Site Status

ShORe Investigational Site

Prague, , Czechia

Site Status

ShORe Investigational Site

Prague, , Czechia

Site Status

ShORe Investigational Site

Sokolov, , Czechia

Site Status

ShORe Investigational Site

Aarhus, , Denmark

Site Status

ShORe Investigational Site

Glostrup Municipality, , Denmark

Site Status

ShORe Investigational Site

Sønderborg, , Denmark

Site Status

ShORe Investigational Site

Nice, Alpes-Maritimes, France

Site Status

ShORe Investigational Site

Strasbourg, Bas Rhin, France

Site Status

ShORe Investigational Site

Écully, Rhone, France

Site Status

ShORe Investigational Site

Créteil, Val de Marr, France

Site Status

ShORe Investigational Site

Ulm, Baden Wuerttermberg, Germany

Site Status

ShORe Investigational Site

Heidelberg, Baden-Wurttemberg, Germany

Site Status

ShORe Investigational Site

Goettigen, Lower Saxony, Germany

Site Status

ShORe Investigational Site

Düsseldorf, Nordrhein, Germany

Site Status

ShORe Investigational Site

Münster, Nordrhein, Germany

Site Status

ShORe Investigational Site

Bonn, North Rhine-Westphalia, Germany

Site Status

ShORe Investigational Site

Münster, North Rhine-Westphalia, Germany

Site Status

ShORe Investigational Site

Hamburg, , Germany

Site Status

ShORe Investigational Site

Athens, , Greece

Site Status

ShORe Investigational Site

Ioannina, , Greece

Site Status

ShORe Investigational Site

Pátrai, , Greece

Site Status

ShORe Investigational Site

Budapest, , Hungary

Site Status

ShORe Investigational Site

Miskolc, , Hungary

Site Status

ShORe Investigational Site

Szombathely, , Hungary

Site Status

ShORe Investigational Site

Ahmedabad, Gujarat, India

Site Status

ShORe Investigational Site

Surat, Gujarat, India

Site Status

ShORe Investigational Site

Bangalore, Karnataka, India

Site Status

ShORe Investigational Site

Bangalore, Karnataka, India

Site Status

ShORe Investigational Site

Pune, Maharashtra, India

Site Status

ShORe Investigational Site

Chandigarh, Punjab, India

Site Status

ShORe Investigational Site

Coimbatore, Tamil Nadu, India

Site Status

ShORe Investigational Site

Lucknow, Uttar Pradesh, India

Site Status

ShORe Investigational Site

Kolkata, West Bengal, India

Site Status

ShORe Investigational Site

Mysuru, , India

Site Status

ShORe Investigational Site

Beersheba, , Israel

Site Status

ShORe Investigational Site

Haifa, , Israel

Site Status

ShORe Investigational Site

Kfar Saba, , Israel

Site Status

ShORe Investigational Site

Petah Tikva, , Israel

Site Status

ShORe Investigational Site

Rishon LeZiyyon, , Israel

Site Status

ShORe Investigational Site

Catanzaro, Reggio Calabria, Italy

Site Status

ShORe Investigational Site

Bologna, , Italy

Site Status

ShORe Investigational Site

Chieti, , Italy

Site Status

ShORe Investiagational Site

Genova, , Italy

Site Status

ShORe Investigational Site

Roma, , Italy

Site Status

ShORe Investigational Site

Siena, , Italy

Site Status

ShORe Investigational Site

Udine, , Italy

Site Status

ShORe Investigational Site

Riga, , Latvia

Site Status

ShORe Investigational Site

Batu Caves, Selangor, Malaysia

Site Status

ShORe Investigational Site

Shah Alam, Selangor, Malaysia

Site Status

ShORe Investigational Site

Kuala Lumpur, , Malaysia

Site Status

ShORe Investigational Site

Gdansk, , Poland

Site Status

ShORe Investigational Site

Krakow, , Poland

Site Status

ShORe Investigational Site

Olsztyn, , Poland

Site Status

ShORe Investigational Site

Szczecin, , Poland

Site Status

ShORe Investigational Site

Tarnowskie Góry, , Poland

Site Status

ShORe Investigational Site

Warsaw, , Poland

Site Status

ShORe Investigational Site

Wroclaw, , Poland

Site Status

ShORe Investigational Site

Seongnam-si, Gyeonggi-do, South Korea

Site Status

ShORe Investigational Site

Daegu, Gyeongsangbuk-do, South Korea

Site Status

ShORe Investigational Site

Busan, , South Korea

Site Status

ShORe Investigational Site

Busan, , South Korea

Site Status

ShORe Investigational Site

Gwangju, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Seoul, , South Korea

Site Status

ShORe Investigational Site

Sant Cugat del Vallès, Barcelona, Spain

Site Status

ShORe Investigational Site

Alcalá de Henares, Madrid, Spain

Site Status

ShORe Investigational Site

Pamplona, Navarre, Spain

Site Status

ShORe Investigational Site

Burjassot, Valencia, Spain

Site Status

ShORe Investigational Site

Barcelona, , Spain

Site Status

ShORe Investigational Site

Barcelona, , Spain

Site Status

ShORe Investigational Site

Burgos, , Spain

Site Status

ShORe Investigational Site

Córdoba, , Spain

Site Status

ShORe Investigational Site

Madrid, , Spain

Site Status

ShORe Investigational Site

Madrid, , Spain

Site Status

ShORe Investigational Site

Valencia, , Spain

Site Status

ShORe Investigational Site

Pathum Wan, Bangkok, Thailand

Site Status

ShORe Investigational Site

Chiang Mai, , Thailand

Site Status

ShORe Investigational Site

Khon Kaen, , Thailand

Site Status

ShORe Investigational Site

Pathum Thani, , Thailand

Site Status

ShORe Investigational Site

Kiev, , Ukraine

Site Status

ShORe Investigational Site

Crewe, Cheshire, United Kingdom

Site Status

ShORe Investigational Site

Southampton, Hampshire, United Kingdom

Site Status

ShORe Investigational Site

Leicester, Leicestershire, United Kingdom

Site Status

ShORe Investigational Site

Bristol, Somerset, United Kingdom

Site Status

ShORe Investigational Site

Guildford, Surrey, United Kingdom

Site Status

ShORe Investigational Site

Wolverhampton, West Midlands, United Kingdom

Site Status

ShORe Investigational Site

London, , United Kingdom

Site Status

ShORe Investigational Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Bulgaria Canada Colombia Czechia Denmark France Germany Greece Hungary India Israel Italy Latvia Malaysia Poland South Korea Spain Thailand Ukraine United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPT-302-1004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 COMPLETED PHASE2/PHASE3